fibroblast activation protein inhibitors (Arisaph Pharmaceuticals/Tufts University School of Medicine)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namefibroblast activation protein inhibitors (Arisaph Pharmaceuticals/Tufts University School of Medicine)
Drug Alias NameARI-3099
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArisaph Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTufts UniversityArisaph Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A